

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## 上海復旦張江生物醫藥股份有限公司

**Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.\***

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 8231)**

### **POSITIVE PROFIT ALERT**

This announcement is made by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (上海復旦張江生物醫藥股份有限公司) (the “**Company**”) pursuant to Inside Information Provisions (as defined under the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”)) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong) and Rule 17.10 of the GEM Listing Rules.

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, the Company and its subsidiaries (the “**Group**”) are expected to record a substantial increase in profits for the year ended 31 December 2012 as compared to the profits in the year 2011. Such increase in profits is mainly attributable to the significant increase in the Company's sales during such period.

The information contained in this announcement is only based on the preliminary assessment by the management of the Company according to the management accounts of the Group, which have not been confirmed nor audited by the Company's auditors. Details of the audited consolidated annual results of the Group for the year ended 31 December 2012 are expected to be announced in March 2013.

**Shareholders and potential investors should exercise caution when dealing in the H Shares of the Company.**

By Order of the Board  
**Wang Hai Bo**  
Chairman

As at the date on the publication of this announcement, the Board comprises:

- Mr. Wang Hai Bo (Executive Director)
- Mr. Su Yong (Executive Director)
- Mr. Zhao Da Jun (Executive Director)
- Ms. Fang Jing (Non-executive Director)
- Mr. Hao Hong Quan (Non-executive Director)
- Mr. Zhu Ke Qin (Non-executive Director)
- Ms. Ke Ying (Non-executive Director)
- Mr. Shen Bo (Non-executive Director)
- Mr. Pan Fei (Independent Non-executive Director)
- Mr. Cheng Lin (Independent Non-executive Director)
- Mr. Weng De Zhang (Independent Non-executive Director)

**Shanghai, the PRC**

31 January 2013

*\* For identification purpose only*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the GEM website on the “Latest Company Announcements” page for at least 7 days from the date of its posting.*